Enoblituzumab

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer.[1] Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

Enoblituzumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
TargetB7-H3
Clinical data
Other namesMGA271
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6474H9990N1726O2030S42
Molar mass145.8 kg/mol g·mol−1

This drug was developed by MacroGenics, Inc.

References
  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Enoblituzumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.